(Total Views: 225)
Posted On: 03/05/2019 12:01:28 PM
Post# of 36566
Since the board is quiet, I'm going to share a private message I sent to a new member here that has been private messaging me. The question was do I truly believe that GNBT will be able to uplist to Nasdaq. My reply was
"I do think they will get there. However I don't think they will get there in the 30-90 days he was saying on the conf call. I guess it will all depend on the NGIO listing. If they get investors, and get a good price and merge with another company and go public, we could see a few hundred million in market cap. If that is the case, and GNBT holds 70% of NGIO afterwards, then that adds $210M to GNBT market cap, divided by 60M shares, so that adds $3.50/share to the already price of $1.60, so now $5.10/share and can uplist.
Let's hope it all works out that way. "
I think our uplisting will take quite a bit of time, with several quarters of increasing revenue from all the recent acquisitions, and future ones. However we can get there quicker if NGIO has a good outing, can merge with that private company, can get some institutional investment (private investment) and then get listed. If we can pull in the $300M value Antigen was valued at a few years ago, then we may get to uplist sooner.
"I do think they will get there. However I don't think they will get there in the 30-90 days he was saying on the conf call. I guess it will all depend on the NGIO listing. If they get investors, and get a good price and merge with another company and go public, we could see a few hundred million in market cap. If that is the case, and GNBT holds 70% of NGIO afterwards, then that adds $210M to GNBT market cap, divided by 60M shares, so that adds $3.50/share to the already price of $1.60, so now $5.10/share and can uplist.
Let's hope it all works out that way. "
I think our uplisting will take quite a bit of time, with several quarters of increasing revenue from all the recent acquisitions, and future ones. However we can get there quicker if NGIO has a good outing, can merge with that private company, can get some institutional investment (private investment) and then get listed. If we can pull in the $300M value Antigen was valued at a few years ago, then we may get to uplist sooner.
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
